Development of Pandemic Vaccines: ERVEBO Case Study (pmc.ncbi.nlm.nih.gov)

• ERVEBO is an FDA- and EMA-approved Ebola vaccine developed by Merck.
• It uses a recombinant vesicular stomatitis virus vector expressing Zaire ebolavirus glycoprotein.
• Ring vaccination trials in Guinea showed 100% efficacy in a cluster-randomized study.
• The case study highlights regulatory flexibility and public-private partnerships.

"The article details the development of ERVEBO (rVSV-ZEBOV), the first FDA-approved Ebola vaccine, as a case study for pandemic vaccine development. It covers clinical trials, regulatory approvals, and real-world efficacy in ring vaccination campaigns in the Democratic Republic of Congo and Guinea. The case study highlights the collaborative efforts of WHO, CEPI, Gavi, and Merck, demonstrating accelerated development pathways. Key lessons include adaptive trial designs, cold chain logistics, and community engagement. The model is proposed for future pandemic preparedness."